Diagnosis of endometrial cancer is primarily based on symptoms and imaging, with early-stage disease being difficult to diagnose. Therefore, development of potential diagnostic biomarkers is required. Metabolomics, a quantitative measurement of the dynamic metabolism in living systems, can be applied to determine metabolite profiles in different disease states. Here, serum metabolomics was performed in 46 early stage endometrial cancer patients and 46 healthy volunteers. In addition, the effect of identified metabolites on tumor cell behavior (invasion, migration, proliferation, apoptosis and autophagy) was examined in endometrial cancer cell lines. Compared with controls, phenylalanine, indoleacrylic acid (IAA), phosphocholine and lyso-platelet-activating factor-16 (lyso-PAF) were differentially detected in patients.
premenopausal women the degree of irregular bleeding is low and often ignored. 2 Transvaginal ultrasound examination can image the size and shape of the uterine cavity, endometrial thickness, polyps and neoplasm invasiveness, but the cut-off level of endometrial thickness in abnormal bleeding in premenopausal women is still controversial and unclear for malignancy diagnosis. 3 The "gold-standard"
for diagnosis of EC is histological assessment of curettage and endometrial biopsy, but 60% of endometrial intraepithelial neoplasia can be misdiagnosed because of an inability to detect tiny local foci. [4] [5] [6] Therefore, early and accurate diagnostic methodology, specific to different stages of endometrial cancer, is required.
Metabolomics, a noninvasive diagnostic technology that focuses on the metabolite profiles involved in disease perturbations and provides a characteristic fingerprint in disease, has been applied to clinical studies of many diseases, including different cancers. [7] [8] [9] [10] [11] It is regarded to be a sensitive, accurate and high-throughput platform In the present study, serum metabolite profiling was performed in endometrial cancer patients and healthy female volunteers. The potential role of the differentially expressed metabolites in cellular migration, invasion, proliferation, apoptosis and autophagy, using Ishikawa and AN3 CA endometrial cancer cell lines, was investigated.
2 | ME TH ODS 
| Sample preparation
A 5-mL fasting venous blood sample was collected from each woman enrolled in the study and serum was separated by centrifugation at 1500 g for 10 minutes and stored at À80°C until processing for metabolomics. All the samples were thawed at 4°C prior to analysis and 0.3 mL serum per sample was drawn, mixed with 0.9 mL methanol, vortexed for 2 minutes, and centrifuged at 18 188 g at 4°C for 10 minutes. ance of accuracy and reproducibility of the mass-to-charge ratio (m/z).
| Data processing and analysis
The metabolomics data were exported through MarkerLynx-V4. 
| Cell migration assay

| Cell invasion assay
Cell invasion was examined by Matrigel-coated transwell assays.
Cells were plated at 1. 2.10 | Cell survival assay 2.12 | Cell autophagy assay 
| Cell proliferation assay
| Western blot assay
Cell lysates, after protein determination by Bio-Rad protein assay, were submitted to 12% SDS-PAGE for protein separation, which were then transferred onto a PVDF membrane. After blocking at room temperature for 2 hours, the membrane was incubated at 4°C overnight with specific antibodies, including E-cadherin 
| Statistics
Each independent experiment was performed in triplicate and repeated 3 times for metabolite functional analysis. Data are presented as mean AE SD. Data were analyzed by 1-way ANOVA followed by Tukey's post-hoc test (GraphPad Prism 6, GraphPad, La Jolla, USA). P < .05 was considered statistically significant.
| RESULTS
| Serum metabolomic profiling
All the serum samples were analyzed on the UPLC-Q-TOF/MS platform and serum metabolites in patients and volunteers were well separated in both positive and negative ion modes (Figure 1A ,B) (linear elution programs can be seen in Tables S1 and   S2 ). The raw data were collected in positive and negative ion mode, respectively (Tables S3 and S4) Umetrics AB, Ume a, Sweden).
The serum metabolite profile in each sample was therefore created. All the discriminative metabolites identified by their differential profiling were ranked by their respective value of variable importance in projection (VIP) and independent t test in positive and negative ion modes, and screened with the significance threshold defined by VIP > 1.5 and P < .05 (Tables S5 and S6 Table 2 ).
| Confirmation of differential production of the serum metabolites between patients and healthy volunteers
The serum concentration of the metabolites, including phenylalanine ( Figure 3A) , IAA ( Figure 3B ), phosphocholine ( Figure 3C ) and PAF Value >1 indicates upregulation of the metabolite in the serum of endometrial cancer patients compared with healthy control serum.
F I G U R E 3
Measurement of the serum concentration of phenylalanine, indoleacrylic acid, phosphocholine and plateletactivating factor-16 in endometrial cancer patients and healthy volunteers. *P < .05, **P < .01. EC, endometrial cancer have been shown in endometrial cancer samples. 32 Moreover, choline kinase-a activation together with the levels of total choline and phosphocholine are augmented during breast cancer development. 33 An increased ratio of phosphocholine/glycerophosphocholine is correlated with malignant transformation in breast and ovarian cancers. [34] [35] [36] These studies highlight the role of phosphocholine in the development of malignant tumors.
Physiologically, phosphocholine is a substrate for the synthesis of lysophosphatidic acid (LPA) which is a bioactive phospholipid with a potent regulatory effect on cellular proliferation, migration, invasion and survival, as well as changes in morphology and differentiation. [37] [38] [39] Moreover, it has been shown that phospholipase D2 and A2 (enzymes responsible for LPA synthesis) as well as LPA receptors 1 and 2 are all overexpressed in cancerous endometrium of type-1 endometrial cancer patients; 40 therefore, it is possible that phosphocholine could be a potential regulator for malignancy development, such as metastasis. In addition, phosphocholine is also overproduced in grade III endometrioid endometrial cancer patients, 32 indicating its role during the development of endometrial cancer.
In conclusion, serum metabolomics was performed in stage I endometrioid endometrial cancer patients and healthy volunteers.
For the first time, 4 metabolites were selected from the differentially expressed metabolites for functional analyses, and they had differing effects on tumor cell behavior. However, the role of IAA, PAF and phenylalanine in immunomodulation of endometrial cancer, as well as the effect of phosphocholine and LPA synthesis on endometrial cancer metastasis, requires further study. Their potential application for early and accurate diagnosis of endometrial cancer still needs to be determined.
